©The Author(s) 2025.
World J Gastrointest Pharmacol Ther. Dec 5, 2025; 16(4): 110642
Published online Dec 5, 2025. doi: 10.4292/wjgpt.v16.i4.110642
Published online Dec 5, 2025. doi: 10.4292/wjgpt.v16.i4.110642
Table 3 Analysis of patients weaned from parenteral support after 24 weeks, n (%)
| Not weaned (n = 33) | Weaned (n = 12) | P value1 | |
| Study cohort | |||
| Adult | 15 (45.5) | 6 (50) | |
| Pediatric | 18 (54.5) | 6 (50) | 0.19 |
| Anatomy type | |||
| Type 1 | 2 (6.1) | 1 (8.3) | |
| Type 2 | 23 (69.7) | 6 (50) | 0.12 |
| Type 3 | 8 (24.2) | 5 (41.7) | |
| Time from PS to treatment, mean (SD) | 7.0 (5.9) | 7.5 (6.4) | 0.76 |
| Remanent small bowel length (cm), mean (SD) | 40.9 (40) | 57.9 (38) | 0.11 |
| Weekly baseline PS volume (mL), mean (SD) | 11541 (4634) | 7441 (4850) | 0.02 |
- Citation: Solar Muñiz H, Fernández A, Busoni V, Martínez MI, Rumbo C, De Barrio S, Saure C, Balacco M, Buncuga MG, Dlugoszweski C, Manzur A, Rudi L, Matoso MD, Cosentino S, Ussher F, Manzur F, Demarchi J, Malaver E, Brion L, Ungar L. Real-world effectiveness and safety of teduglutide in adult and pediatric patients with short bowel syndrome in Argentina. World J Gastrointest Pharmacol Ther 2025; 16(4): 110642
- URL: https://www.wjgnet.com/2150-5349/full/v16/i4/110642.htm
- DOI: https://dx.doi.org/10.4292/wjgpt.v16.i4.110642